Aude Georgiana Chapuis

USPTO Granted Patents = 7 (Patent Applications = 8)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 8)

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

7 out of 289

Fred Hutchinson Cancer Center

patents

2 out of 57

Adaptive Biotechnologies Corporation

patents

1 out of 2,104

University of Washington

patents

where one patent can have more than one assignee

Years Active: 2021-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448430 - High avidity WT1 T cell receptors and uses thereof (2025-10-21),

2. 11534461 - High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof (2022-12-27),

3. 11458191 - Binding proteins specific for RAS neoantigens and uses thereof (2022-10-04),

4. 11382954 - Binding proteins specific for RAS neoantigens and uses thereof (2022-07-12),

5. 11041202 - Method of identifying human compatible T cell receptors specific for an antigenic target (2021-06-22),

6. 11034748 - High affinity MAGE-A1-specific TCRs and uses thereof (2021-06-15),

7. 11026969 - High affinity T cell receptors and uses thereof (2021-06-08),

Title: Aude Georgiana Chapuis: Innovator in Cancer Immunotherapy

Introduction

Aude Georgiana Chapuis is a prominent inventor based in Seattle, WA, known for her significant contributions to cancer immunotherapy. With a total of 7 patents, her work focuses on developing T cell receptors that target specific tumor-associated antigens, paving the way for innovative treatments in oncology.

Latest Patents

Among her latest patents, Aude has developed high avidity WT1 T cell receptors and related binding proteins. These T cell receptors exhibit high functional avidity against the tumor-associated antigen p37 from Wilms tumor protein 1 (WT1). This innovation is crucial for treating diseases where cells overexpress WT1 and/or produce the p37 antigen, particularly in cancer. Another notable patent involves high affinity Merkel cell polyomavirus T antigen-specific TCRs. This patent provides binding proteins and TCRs with high affinity and specificity against Merkel cell polyomavirus T antigen epitopes, which are essential for treating Merkel cell carcinoma.

Career Highlights

Aude has worked with esteemed organizations such as the Fred Hutchinson Cancer Center and Adaptive Biotechnologies Corporation. Her experience in these institutions has allowed her to advance her research and contribute to the field of cancer treatment significantly.

Collaborations

Throughout her career, Aude has collaborated with notable professionals, including Thomas M Schmitt and Philip D Greenberg. These collaborations have further enriched her research and innovation in cancer immunotherapy.

Conclusion

Aude Georgiana Chapuis stands out as a leading inventor in the field of cancer immunotherapy, with her patents reflecting her commitment to advancing treatment options for patients. Her work continues to inspire and drive innovation in the medical community.

This text is generated by artificial intelligence and may not be accurate.